#Germany #Marburg #DRG Instruments #TBI Testing #MEDLAB Dubai

DRG's Innovative Approach to Traumatic Brain Injury Testing

In a significant advancement for medical diagnostics, DRG Instruments GmbH, a leading developer of immunoassays for over five decades, has unveiled its latest innovations in the field of traumatic brain injury (TBI) testing at the MEDLAB event in Dubai. This initiative marks the inception of DRG Neuroscience, a new division entirely focused on addressing brain health issues, particularly TBI.

The company introduced fully automated CLIA tests that aim to streamline the evaluation of suspected traumatic brain injuries. The revolutionary tests, which combine GFAP and UCH-L1 measurements, are designed for use on DRG's automated platform, DxDATA™, effectively allowing healthcare professionals to assess blood levels of these biomarkers within a swift 30-minute timeframe. This rapid turnaround is particularly crucial when serum samples are collected within 12 hours following a suspected TBI incident.

Enhancing Patient Care with Speedy Diagnostics

Joerg Schloesser, Managing Director and Vice President of Business Division at DRG, emphasized the importance of these solutions, stating, "We are thrilled to bring these innovative TBI solutions to the global market. Leveraging automated testing and quick turnaround times enables healthcare professionals to make faster and better-informed decisions. Our mission is to advance patient care for those suffering from TBIs worldwide."

This automated testing not only increases the chances of immediate and effective treatment but also reduces the reliance on radiation-based diagnostic imaging, which can be a concern for many patients. By providing clinicians with reliable test results quickly, DRG aims to facilitate timely interventions that can significantly improve patient outcomes.

Compliance and Accessibility

The TBI tests developed by DRG meet CE marking standards and conform to the requirements set forth by the Clinical and Laboratory Standards Institute (CLSI). Specifically designed for clinical laboratory settings, these tests are intended for patients aged 18 years and above, ensuring that they can be effectively integrated into routine clinical practice.

Healthcare professionals interested in utilizing DRG's TBI testing solutions can reach out to their local sales representatives for information regarding availability in their regions. They can also get in touch via email for further details on these tests.

Showcasing Innovations at MEDLAB

DRG will be showcasing its TBI tests at the MEDLAB Middle East exhibition, taking place from February 3rd to February 6th at the Dubai World Trade Centre. Attendees can visit Hall 1, Stand G50, where the product development team will be on hand to address any inquiries regarding the technology or its applications in clinical settings.

A Legacy of Excellence in Diagnostics

Founded in 1973 and headquartered in Marburg, Germany, DRG Instruments has been at the forefront of innovative immunoassay development since 1990. The company’s expansive reach includes partnerships with distribution networks in over 120 countries, allowing for widespread access to its pioneering medical solutions, including the DRGHYBRiD-XL®, an automated analyzer for immunoassays and clinical chemistry. DRG holds certifications like ISO 13485 and complies with FDA regulations, reinforcing its commitment to quality in healthcare diagnostics.

In conclusion, DRG's recent launch of TBI testing exemplifies its dedication to enhancing patient care through rapid and reliable diagnostic methods. As healthcare continues to evolve, innovations like these are crucial for ensuring timely and effective responses to traumatic brain injuries across the globe.